Table of Content

Open Access iconOpen Access

ARTICLE

Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients

Bruce L. Jacobs1, Marc C. Smaldone1, Vikas Tyagi1, Brian J. Philips1, Stephen V. Jackman1, Wendy W. Leng1, Pradeep Tyagi2

1 Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
2 Department of Urology, William Beaumont Hospital, Royal Oak, Michigan, USA
Address correspondence to Dr. Bruce L. Jacobs, Department of Urology, University of Pittsburgh Schoolof Medicine, 3471 Fifth Avenue, Suite 700, Pittsburgh, PA15213-3232 USA

Canadian Journal of Urology 2010, 17(1), 4989-4994.

Abstract

Objectives: Studies have suggested that pathology of the lower urinary tract can be detected by following changes in urinary proteins. We evaluated urine nerve growth factor (NGF) levels from patients with a variety of urologic conditions to examine NGF's role as a future biomarker.
Materials and methods: Urine samples were obtained from 72 patients with normal non-diseased urinary tracts (n=13), neurogenic overactive bladder (NOAB) (n=13), idiopathic overactive bladder (OAB) (n=17), interstitial cystitis/painful bladder syndrome (IC/PBS) (n=8), prostate cancer (n=7), history of prostate cancer status post robot-assisted laparoscopic prostatectomy (RALP) (n=6), active bladder cancer (n=4), and nephrolithiasis (n=4). Urinary NGF levels were measured by enzyme linked immunosorbent assay (ELISA) using the Emax ImmunoAssay System (Promega, Madison, WI, USA); each NGF level was normalized to the patient's urine creatinine (Cr) level. The Bonferroni correction was used to adjust for multiple comparisons.
Results: Urinary NGF/Cr levels were significantly elevated in patients with NOAB (23.02 pg/mg (0-293), p=0.004) and IC/PBS (31.24 pg/mg (0-291), p=0.006); and approached significance in patients with nephrolithiasis (19.46 pg/mg (0-85), p=0.06) compared to controls (0.00 pg/mg (0-12).
Conclusions: Urinary NGF levels were significantly elevated in patients with NOAB and IC/PBS. Future studies are needed to further examine the significance of urinary NGF levels in the pathogenesis of a variety of urologic diseases and whether NGF could be used as a diagnostic or prognostic marker for specific urologic diseases.

Keywords

interstitial cystitis/painful bladder syndrome, neurogenic overactive bladder, nerve growth factor, urine, biomarker

Cite This Article

APA Style
Jacobs, B.L., Smaldone, M.C., Tyagi, V., Philips, B.J., Jackman, S.V. et al. (2010). Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients. Canadian Journal of Urology, 17(1), 4989–4994.
Vancouver Style
Jacobs BL, Smaldone MC, Tyagi V, Philips BJ, Jackman SV, Leng WW, et al. Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients. Can J Urology. 2010;17(1):4989–4994.
IEEE Style
B.L. Jacobs et al., “Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients,” Can. J. Urology, vol. 17, no. 1, pp. 4989–4994, 2010.



cc Copyright © 2010 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 138

    View

  • 107

    Download

  • 0

    Like

Share Link